Adverse Effects Associated With Newer Diabetes Therapies.

about

Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice.

P2860

Q41081573-1DEE6B5D-7DC2-42CE-97CB-2FE76A3DFF41

P2860

Adverse Effects Associated With Newer Diabetes Therapies.

Item

http://www.wikidata.org/entity/Q38546214

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Adverse Effects Associated With Newer Diabetes Therapies.

@en

type

Item

label

Adverse Effects Associated With Newer Diabetes Therapies.

@en

prefLabel

Adverse Effects Associated With Newer Diabetes Therapies.

@en

P1476

Adverse Effects Associated With Newer Diabetes Therapies.

@en

P2093

Adebola A Adesoye

http://www.w3.org/2001/XMLSchema#string

Oluwaranti F Akiyode

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

P304

238-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0897190015594732

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26169212

http://www.w3.org/2001/XMLSchema#string

Adverse Effects Associated With Newer Diabetes Therapies.

about

P2860

P2860

Adverse Effects Associated With Newer Diabetes Therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698